Found: 15
Select item for more details and to access through your institution.
Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy.
- Published in:
- PLoS ONE, 2023, v. 17, n. 4, p. 1, doi. 10.1371/journal.pone.0283669
- By:
- Publication type:
- Article
6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0083400
- By:
- Publication type:
- Article
Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Revised upper limb module for spinal muscular atrophy: 12 month changes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Revised upper limb module for spinal muscular atrophy: Development of a new module.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy.
- Published in:
- Developmental Medicine & Child Neurology, 2013, v. 55, n. 11, p. 1038, doi. 10.1111/dmcn.12213
- By:
- Publication type:
- Article
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy.
- Published in:
- Developmental Medicine & Child Neurology, 2012, v. 54, n. 10, p. 879, doi. 10.1111/j.1469-8749.2012.04345.x
- By:
- Publication type:
- Article
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
- Published in:
- Journal of Neurology, 2023, v. 270, n. 5, p. 2531, doi. 10.1007/s00415-023-11560-1
- By:
- Publication type:
- Article
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment.
- Published in:
- European Journal of Neurology, 2023, v. 30, n. 7, p. 1945, doi. 10.1111/ene.15499
- By:
- Publication type:
- Article
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.
- Published in:
- PLoS ONE, 2017, v. 12, n. 2, p. 1, doi. 10.1371/journal.pone.0172346
- By:
- Publication type:
- Article
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study.
- Published in:
- PLoS ONE, 2016, v. 11, n. 3, p. 1, doi. 10.1371/journal.pone.0151445
- By:
- Publication type:
- Article
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression.
- Published in:
- PLoS ONE, 2018, v. 13, n. 6, p. 1, doi. 10.1371/journal.pone.0199657
- By:
- Publication type:
- Article